The Food and Drug Administration rejected Novo Nordisk’s application to sell a once-weekly insulin treatment called icodec, sending the Danish drugmaker a series of requests related to manufacturing and its potential use in Type 1 diabetes.
The Food and Drug Administration rejected Novo Nordisk’s application to sell a once-weekly insulin treatment called icodec, sending the Danish drugmaker a series of requests related to manufacturing and its potential use in Type 1 diabetes.